PMD Psychemedics Corp.

Robyn C. Davis Joins Psychemedics Board of Directors

Robyn C. Davis Joins Psychemedics Board of Directors

ACTON, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Psychemedics Corporation (NASDAQ: PMD) announced that Robyn C. Davis was unanimously elected to serve on the Board of Directors of Psychemedics Corporation effective immediately. Ms. Davis will be filling the vacancy created by the untimely passing this past December of Clint Allen, a long- time and dedicated Psychemedics board member.

Ray Kubacki, Chairman and CEO stated “We are excited to have Robyn join our board. She brings a wealth of experience and a balanced perspective in a number of areas particularly in life sciences and strategy that will prove most helpful to Psychemedics growth as we move forward.”

Ms. Davis currently serves as a corporate Director for Brooks Automation (BRKS), a $900 million revenue global leader in robotics serving the semiconductor and life sciences markets. She has served on the Audit, Compensation and Finance committees. Additionally, Robyn serves as a Director for Akston Bioscience, an early- stage specialty pharmaceutical company that develops novel biologic therapeutics for diabetes and vaccines.

Ms, Davis is also a Managing Director of Angel Healthcare Investors where she has managed early-stage investments in medical devices, life sciences, information technology and professional services over the past 20 years.

Throughout her career, Ms. Davis has advised governments, boards, CEO’s, and senior executives on value-creation, growth strategy, cost reduction, and leadership development. She has worked as an independent advisor as well as a Consultant at Bain & Co. and a Director at Barents, LLC.

Ms. Davis holds an Executive Masters Professional Director Certification from the American College of Corporate Directors and was also recognized by Women, Inc. magazine as a “Most Influential Corporate Director” in 2019. She is a graduate of Tufts University and Harvard Business School.

Psychemedics Corporation is the world’s largest provider of hair testing for the detection of drugs of abuse. The Company’s patented process is used by thousands of U.S. and international clients, including over 10% of the Fortune 500 companies, for pre-employment and random drug testing. Major police departments, Federal Reserve Banks, schools, and other public entities also rely on our unique patented drug testing process. We strongly believe our drug testing method to be superior to any other product currently in use, including traditional urine testing and other hair testing methods. The Psychemedics web site is .

Contact: Raymond C. Kubacki, Chairman, President and CEO

Phone: (978) 206-8220



EN
17/03/2021

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Psychemedics Corp.

 PRESS RELEASE

Psychemedics Releases 2025 Workforce Insights Report

Psychemedics Releases 2025 Workforce Insights Report Synthetic Drug Threats and Legalization Risks Shape a New Era for Workplace Safety DALLAS, June 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair testing for drugs of abuse, today announced the release of its second annual Workforce Insights Report, providing a comprehensive look at the evolving drug landscape and its impact on workplace safety, hiring practices, and employer risk. The 2025 Psychemedics Insights Report draws from the largest proprietary database of hair drug testing results in the industr...

 PRESS RELEASE

Psychemedics Named “Most Innovative Drug Testing Company of the Year”

Psychemedics Named “Most Innovative Drug Testing Company of the Year” DALLAS, May 16, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, the world’s leading provider of hair drug testing, is proud to announce it has been named “Most Innovative Drug Testing Company of the Year” by Acquisition International Magazine as part of its prestigious 2025 Global Excellence Awards. This recognition honors Psychemedics’ continued leadership in advancing the science of drug detection, including the recent launch of its Enhanced Quartile Reporting. This breakthrough analytics tool provides deeper insi...

 PRESS RELEASE

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced D...

Psychemedics Launches Groundbreaking Quartile Reporting for Enhanced Drug Testing Insights DALLAS, March 03, 2025 (GLOBE NEWSWIRE) -- Psychemedics Corporation, a global leader in hair drug testing, is proud to announce the launch of its innovative Quartile Reporting feature. This industry-first enhancement empowers organizations with unprecedented insights into drug test results, enabling data-driven decision-making and fostering safer, more productive workplaces. The new Quartile Reporting feature allows clients to see where a candidate’s or employee’s test results fall within a range o...

Jonathan Moreland
  • Jonathan Moreland

InsiderInsights Weekly Report: December 14, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

ResearchPool Subscriptions

Get the most out of your insights

Get in touch